2.58%
-8.70%
-53.36%
-63.87%
-65.95%
-38.97%
-81.10%
14.00014.00012.00012.00010.00010.0008.0008.0006.0006.0004.0004.00011/29/202411/29/202412/10/202412/10/202412/21/202412/21/20241/2/20251/2/20251/13/20251/13/20251/24/20251/24/20252/5/20252/5/20252/16/20252/16/2025
Download SVG
Download PNG
Download CSV

Company Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.


In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors.The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.Y-mAbs Therapeutics, Inc.


was incorporated in 2015 and is headquartered in New York, New York.

Market Data

Last Price 5.56
Change Percentage 2.58%
Open 5.41
Previous Close 5.42
Market Cap ( Millions) 249
Volume 587160
Year High 20.9
Year Low 5.28
M A 50 6.85
M A 200 11.21

Financial Ratios

FCF Yield -8.79%
Dividend Yield 0.00%
ROE -24.61%
Debt / Equity 1.16%
Net Debt / EBIDTA 240.57%
Price To Book 2.68
Price Earnings Ratio -10.4
Price To FCF -11.38
Price To sales 2.95
EV / EBITDA -6.53

News

Business Breakdown

Expected Mid-Term Growth

Segment n°1 -> Novel Antibody-based Therapeutic Products

Expected Growth : 10.27 %

What the company do ?

Y-mAbs Therapeutics' novel antibody-based therapeutic products target cancer and rare diseases, utilizing bispecific antibodies and antibody-drug conjugates for innovative treatments.

Why we expect these perspectives ?

Y-mAbs Therapeutics, Inc.'s novel antibody-based therapeutic products are driven by increasing demand for targeted cancer treatments, advancements in immunotherapy, and a growing pipeline of products in late-stage clinical trials. Strong partnerships, strategic collaborations, and a robust intellectual property portfolio also contribute to the company's 10.27% growth.

Y-Mabs Therapeutics, Inc. Products

Product Range What is it ?
Naxitamab A monoclonal antibody that targets GD2, a glycoprotein expressed on the surface of neuroblastoma cells, used for the treatment of high-risk neuroblastoma in patients one year of age and older and in bone marrow who have achieved at least a partial response to prior therapy.
Omburtamab A monoclonal antibody that targets B7-H3, a protein expressed on the surface of certain cancer cells, used for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma.
YM155 A small molecule inhibitor of survivin, a protein that inhibits apoptosis (cell death), used for the treatment of various types of cancer, including melanoma, lung, and breast cancer.

Y-mAbs Therapeutics, Inc.'s Porter Forces

Y-mAbs Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and rare diseases. However, the company's focus on developing novel antibody-based therapies may reduce the threat of substitutes.

Y-mAbs Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective cancer and rare disease treatments.

Y-mAbs Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services. However, the company's dependence on a few key suppliers may increase the bargaining power of suppliers.

Y-mAbs Therapeutics, Inc. has a high threat of new entrants due to the growing interest in antibody-based therapies and the increasing investment in biotechnology research and development.

Y-mAbs Therapeutics, Inc. operates in a highly competitive industry with many established players and new entrants. The company faces intense rivalry from other biotechnology companies, which may lead to increased competition for market share and talent.

Capital Structure

Value
Debt Weight 1.39%
Debt Cost 3.95%
Equity Weight 98.61%
Equity Cost 7.79%
WACC 7.74%
Leverage 1.41%

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
LGND Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which …
ARDX Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, …
BYSI BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent …
APLT Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for …
CDXC ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
5.56$
Current Price
5.56$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

ValueQualityYieldMomentumVolatilityGrowth
Company A-Score: 6.00Peer Group Average: 5.80Leader: 5.80

Peers Group Analysis

🥇

BeyondSpring Logo
BeyondSpring
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥈

Ligand Pharmaceuticals Logo
Ligand Pharmaceuticals
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥉

ChromaDex Logo
ChromaDex
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Applied Therapeutics Logo
Applied Therapeutics
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

Y-mAbs Therapeutics Logo
Y-mAbs Therapeutics
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

Ardelyx Logo
Ardelyx
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->